The US FDA’s Antimicrobial Drugs Advisory Committee on Aug. 7 strongly supported approval of Insmed Inc.’s amikacin liposome inhalation suspension (ALIS) in nontubercuolous mycobacterial (NTM) lung disease but for a narrower indication than that sought by the company.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?